Page last updated: 2024-08-23

paroxetine and Parkinson Disease

paroxetine has been researched along with Parkinson Disease in 22 studies

Research

Studies (22)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (4.55)	18.7374
1990's	3 (13.64)	18.2507
2000's	9 (40.91)	29.6817
2010's	7 (31.82)	24.3611
2020's	2 (9.09)	2.80

Authors

Authors	Studies
Carrasco-Carballo, A; Chamorro-Arenas, D; Hernández-Arrambide, PE; Luna, F; Martínez, I; Mendieta, L; Parra, I; Sartillo-Piscil, F; Tizabi, Y	1
Chen, ML; Gou, L; Jiang, DQ; Jiang, LL; Mo, Y; Wang, Y; Wu, YL; Zang, QM	1
Auinger, P; Christine, CW; Factor, SA; Juncos, J; Leentjens, AF; Lyness, JM; Marsh, L; McDonald, W; Moonen, AJ; Panisset, M; Pfeiffer, R; Richard, IH; Rottenberg, D; Serrano Ramos, C; Shulman, L; Singer, C; Slevin, J; Wijers, A	1
Broen, MP; Köhler, S; Kuijf, ML; Leentjens, AF; McDonald, WM; Richard, IH	1
Desbordes, M; Gaillon, G; Guillaume, M; Hébant, B; Lefaucheur, R; Maltête, D	1
Bienfait, K; Buyske, S; Dicke, A; Dobkin, RD; Gara, M; Marin, H; Mark, MH; Menza, M	2
Bienfait, KL; Dicke, A; Dobkin, RD; Gara, M; Marin, H; Mark, MH; Menza, M; Tröster, A	1
Bienfait, KL; Dicke, A; Dobkin, RD; Friedman, J; Gara, M; Marin, H; Mark, MH; Menza, M	1
Friedman, JH; Weintraub, D	1
Black, KJ; Brodsky, M; Christine, CW; Como, PG; Elmer, L; Factor, SA; Fernandez, HH; Horn, S; Hyson, HC; Jiang, W; Juncos, J; Kurlan, R; Lyness, JM; Manning, C; Marsh, L; McDermott, MP; McDonald, W; Panisset, M; Pearson, N; Pfeiffer, R; Press, D; Richard, IH; Rottenberg, D; Serrano Ramos, C; Shulman, L; Singer, C; Slevin, J	1
Schölzel-Dorenbos, CJ	1
Carlson, NE; Chung, KA; Nutt, JG	1
Hamada, Y; Inatsugi, Y; Kusunoki, S; Miyamoto, K; Suzuki, H	1
Alarcón, J; Cabrera-Valdivia, F; García-Albea, E; Jiménez-Jiménez, FJ; Martínez-Junquera, G; Tejeiro, J	1
Iacono, RP; Toyama, SC	1
Alder, JT; Bray, L; Chen, CP; Foster, OJ; Francis, PT; Kingsbury, AE	1
Antonini, A; Canesi, M; Mariani, CB; Pezzoli, G; Tesei, S; Zecchinelli, A	1
Bellini, G; Bonuccelli, U; Ceravolo, R; Dell'Agnello, G; Dell'Osso, L; Gambaccini, G; Murri, L; Nuti, A; Piccinni, A	1
Brenninkmeijer, JH; Freijzer, PL	1
Steur, EN	1
Agid, Y; Cash, R; Raisman, R	1

Reviews

1 review(s) available for paroxetine and Parkinson Disease

Article	Year
The effects of paroxetine therapy on depressive symptom and motor function in the treatment of depression with Parkinson's disease: A meta-analysis. Medicine, 2023, Aug-25, Volume: 102, Issue:34 Topics: Control Groups; Depression; Humans; Mental Status and Dementia Tests; Parkinson Disease; Paroxetine	2023

Trials

8 trial(s) available for paroxetine and Parkinson Disease

Article	Year
Trajectories of recovery in depressed Parkinson's disease patients treated with paroxetine or venlafaxine. Parkinsonism & related disorders, 2016, Volume: 23 Topics: Aged; Antidepressive Agents, Second-Generation; Depression; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Paroxetine; Venlafaxine Hydrochloride	2016
A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology, 2009, Mar-10, Volume: 72, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Tricyclic; Anxiety; Cognition; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Nortriptyline; Parkinson Disease; Paroxetine; Psychiatric Status Rating Scales; Quality of Life; Selective Serotonin Reuptake Inhibitors; Sleep; Social Behavior; Treatment Outcome	2009
The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2009, Jul-15, Volume: 24, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depression; Disability Evaluation; Double-Blind Method; Female; Humans; Male; Middle Aged; Nortriptyline; Parkinson Disease; Paroxetine; Psychiatric Status Rating Scales; Quality of Life; Recurrence; Treatment Outcome	2009
The impact of antidepressant treatment on cognitive functioning in depressed patients with Parkinson's disease. The Journal of neuropsychiatry and clinical neurosciences, 2010,Spring, Volume: 22, Issue:2 Topics: Adult; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cognition Disorders; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Nortriptyline; Parkinson Disease; Paroxetine; Time Factors; Treatment Outcome	2010
Depression in Parkinson's disease: symptom improvement and residual symptoms after acute pharmacologic management. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2011, Volume: 19, Issue:3 Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Dysthymic Disorder; Female; Humans; Male; Middle Aged; Nortriptyline; Parkinson Disease; Paroxetine; Placebos; Psychiatric Status Rating Scales	2011
A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology, 2012, Apr-17, Volume: 78, Issue:16 Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Parkinson Disease; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Venlafaxine Hydrochloride	2012
Short-term paroxetine treatment does not alter the motor response to levodopa in PD. Neurology, 2005, May-24, Volume: 64, Issue:10 Topics: Accidental Falls; Aged; Brain; Cross-Over Studies; Dizziness; Dopamine; Dopamine Agents; Double-Blind Method; Drug Interactions; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Paroxetine; Presynaptic Terminals; Selective Serotonin Reuptake Inhibitors; Serotonin; Treatment Failure; Vestibular Diseases	2005
Tolerability of paroxetine in Parkinson's disease: a prospective study. Movement disorders : official journal of the Movement Disorder Society, 2000, Volume: 15, Issue:5 Topics: Aged; Antiparkinson Agents; Clinical Protocols; Depression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Parkinson Disease; Paroxetine; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome	2000

Other Studies

13 other study(ies) available for paroxetine and Parkinson Disease

Article	Year
Antidepressant and Neuroprotective Effects of 3-Hydroxy Paroxetine, an Analog of Paroxetine in Rats. The international journal of neuropsychopharmacology, 2023, 03-22, Volume: 26, Issue:3 Topics: Animals; Antidepressive Agents; Disease Models, Animal; Male; Neuroprotective Agents; Parkinson Disease; Paroxetine; Rats; Rats, Wistar; Serotonin Plasma Membrane Transport Proteins; Substantia Nigra; Tyrosine 3-Monooxygenase	2023
Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease. Parkinsonism & related disorders, 2014, Volume: 20, Issue:6 Topics: Aged; Antidepressive Agents; Anxiety; Cyclohexanols; Datasets as Topic; Depression; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Parkinson Disease; Paroxetine; Predictive Value of Tests; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Severity of Illness Index; Venlafaxine Hydrochloride	2014
Combination of paroxetine and rasagiline induces serotonin syndrome in a parkinsonian patient. Revue neurologique, 2016, Volume: 172, Issue:12 Topics: Aged; Depressive Disorder, Major; Drug Interactions; Humans; Indans; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome	2016
Glad about SAD (PD). Neurology, 2012, Apr-17, Volume: 78, Issue:16 Topics: Antidepressive Agents; Cyclohexanols; Depressive Disorder; Female; Humans; Male; Parkinson Disease; Paroxetine; Venlafaxine Hydrochloride	2012
[Hallucinations caused by paroxetine taken together with a levodopa-carbidopa preparation]. Nederlands tijdschrift voor geneeskunde, 2002, Aug-31, Volume: 146, Issue:35 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Synergism; Drug Therapy, Combination; Female; Hallucinations; Humans; Levodopa; Parkinson Disease; Paroxetine; Selective Serotonin Reuptake Inhibitors	2002
[A case of Parkinson's disease with neuroleptic malignant syndrome induced by paroxetine]. Rinsho shinkeigaku = Clinical neurology, 2006, Volume: 46, Issue:8 Topics: Aged; Depression; Female; Humans; Neuroleptic Malignant Syndrome; Parkinson Disease; Paroxetine; Selective Serotonin Reuptake Inhibitors	2006
Parkinsonism exacerbated by paroxetine. Neurology, 1994, Volume: 44, Issue:12 Topics: Adult; Depression; Female; Humans; Parkinson Disease; Paroxetine	1994
Is it safe to combine a selective serotonin reuptake inhibitor with selegiline? The Annals of pharmacotherapy, 1994, Volume: 28, Issue:3 Topics: 1-Naphthylamine; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Humans; Parkinson Disease; Paroxetine; Selective Serotonin Reuptake Inhibitors; Selegiline; Sertraline	1994
Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex. Annals of the New York Academy of Sciences, 1998, Dec-15, Volume: 861 Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Humans; Ketanserin; Kinetics; Neocortex; Parkinson Disease; Paroxetine; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Reference Values	1998
Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. Neurology, 2000, Oct-24, Volume: 55, Issue:8 Topics: Aged; Analysis of Variance; Depressive Disorder; Female; Humans; Male; Middle Aged; Parkinson Disease; Paroxetine; Psychomotor Performance	2000
[Hallucinations caused by paroxetine taken together with a levodopa-carbidopa preparation]. Nederlands tijdschrift voor geneeskunde, 2002, Mar-23, Volume: 146, Issue:12 Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Interactions; Drug Therapy, Combination; Female; Hallucinations; Humans; Levodopa; Parkinson Disease; Paroxetine; Selective Serotonin Reuptake Inhibitors	2002
[Hallucinations caused by paroxetine in combined usage of levodopa-carbidopa]. Nederlands tijdschrift voor geneeskunde, 2002, Jun-01, Volume: 146, Issue:22 Topics: Antidepressive Agents, Second-Generation; Antiparkinson Agents; Carbidopa; Drug Interactions; Hallucinations; Levodopa; Parkinson Disease; Paroxetine	2002
Parkinson's disease: decreased density of 3H-imipramine and 3H-paroxetine binding sites in putamen. Neurology, 1986, Volume: 36, Issue:4 Topics: Aged; Binding Sites; Humans; Imipramine; Middle Aged; Parkinson Disease; Paroxetine; Piperidines; Putamen; Tritium	1986